Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Price Performance

NASDAQ:EVGN opened at $1.18 on Monday. The firm’s 50-day moving average price is $1.24 and its 200-day moving average price is $1.54. The company has a market capitalization of $6.33 million, a PE ratio of -0.26 and a beta of 1.37. Evogene has a 1-year low of $0.95 and a 1-year high of $9.00.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. The business had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $3.63 million. During the same quarter in the prior year, the company earned ($1.30) earnings per share.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Jane Street Group LLC acquired a new position in Evogene Ltd. (NASDAQ:EVGN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.40% of Evogene as of its most recent SEC filing. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.